Table 2 Relationship between time to 50%... | American Society of Hematology

Table 2

Relationship between time to 50% reduction in neutrophil or platelet counts and steady-state lenalidomide exposure

Time to ≥ 50% reduction from baseline	Neutrophils			Platelets
Time to ≥ 50% reduction from baseline	n	C_max, ng/mL	AUC_5, h/ng/mL	n	C_max, ng/mL	AUC_5, h/ng/mL
< 28 days	12	218 ± 45	683 ± 187	11	208 ± 49	656 ± 201
≥ 28 days	10	162 ± 96	449 ± 98	9	169 ± 105	460 ± 121
P		.016	.0008		.076	.011

Time to ≥ 50% reduction from baseline	Neutrophils			Platelets
Time to ≥ 50% reduction from baseline	n	C_max, ng/mL	AUC_5, h/ng/mL	n	C_max, ng/mL	AUC_5, h/ng/mL
< 28 days	12	218 ± 45	683 ± 187	11	208 ± 49	656 ± 201
≥ 28 days	10	162 ± 96	449 ± 98	9	169 ± 105	460 ± 121
P		.016	.0008		.076	.011

Hematological data were obtained from 22 patients who received lenalidomide 10 mg daily for up to 28 days during the first cycle. Lenalidomide AUC₅ and C_max were determined on day 14 of the first cycle (at steady state).

Significantly different between the 2 groups (< 28 days or ≥ 28 days to 50% or more reduction from baseline) as shown by 2-sided t test after log-transformation of the exposure data.

View Large

This Feature Is Available To Subscribers Only